Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) all signal through the transmembrane receptor tyrosine kinase RET. The signalling complex consists of GFLs, GPI-anchored ligand binding GDNF family receptor alphas (GFRas) and RET. Signalling via RET is required for the development of the nervous system and the kidney, as well as for spermatogenesis. However, constitutive activation of RET is implicated as a cause in several diseases. Mutations of the RET proto-oncogene cause the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). Recently, it has been suggested that mutations in the persephin binding GFRa4 receptor may have a potentially modifying role in MEN 2. Several naturally occurring, different splice variants of the mammalian GFRa4 have been reported. A 7 bp insertion-mutation in the human GFRa4 gene causes a shift of reading frame and thereby changes the balance between the transcripts encoding GPI-anchored and soluble GFRa4 receptors. We report here that the mammalian soluble GFRa4 can activate RET independently of its preferential ligand, persephin. Our data show that soluble GFRa4 can associate with, and induce, phosphorylation of RET. In addition, our data show that this isoform of GFRa4 can induce downstream signalling, as well as neuronal survival and differentiation, in the absence of persephin. These results suggest that, in line with the previous report, GFRa4 may be a candidate gene for, or modifier of, the MEN 2 diseases.
Inherited multiple endocrine neoplasia type 2 (MEN 2) is a cancer syndrome which, in most patients, is caused by mutations in the proto-oncogene RET (Kodama et al., 2005) . RET is a receptor tyrosine kinase which, under normal conditions, is activated by a complex consisting of a dimeric ligand and a dimeric co-receptor.
There are four different ligands, all of which belong to the glial cell line-derived neurotrophic factor (GDNF) family (GDNF, neurturin, artemin, persephin) , and correspondingly four different GPI-anchored co-receptors, which are named GDNF family receptor alpha (GFRa) 1-4 (Airaksinen and Saarma, 2002) . The persephin binding co-receptor GFRa4 is of special interest, as its restricted expression pattern suggests that it may play a role in the MEN 2 syndrome (Lindahl et al., 2000 (Lindahl et al., , 2001 . Several splice variants of GFRa4 have been found both in the human and in the mouse (Lindahl et al., 2000 (Lindahl et al., , 2001 . The variants have been postulated to encode putative GPI-anchored, transmembrane or soluble receptors. A schematic picture of the mouse GFRa4 splicing variants is shown in Figure 1d . Recently, a mutation, which may contribute to a more aggressive disease course of MEN 2, was identified in human GFRa4 (Vanhorne et al., 2005) . The mutation consists of a 7 bp insertion that causes a frameshift in all of the human GFRa4 splice variants. This mutation affects the C-terminal end of the different forms of the receptor, and thereby seems to alter the balance between GPI-anchored and soluble forms of human GFRa4. Both the human and mouse GPI-anchored variants bind persephin (PSPN) and mediate RET-activation (Lindahl et al., 2001; Yang et al., 2004) , but none of the soluble GFRa4 receptors have ever been characterized.
Generally, the GFRa receptors consist of three homologous cysteine-rich domains (D1, D2, D3), with the exception of the mammalian GPI-anchored GFRa4 receptors that lack the first N-terminal D1. Crystal structure analysis of the D3, as well as functional testing of the GFRa1 model, has located the ligand binding residues to D2 (Scott and Iba´n˜ez, 2001; Leppa¨nen et al., 2004) . Recently, the artemin/GFRa3 complex structure revealed a conserved binding interface in domain 2, and a convergent ligand recognition was suggested (Wang et al., 2006) . We found (Figure 1a-d) that the mouse and human wild-type soluble GFRa4, as well as the two human mutated forms of soluble GFRa4, have in common a preserved D2 with five cysteine bridges and six a-helices. However, all the soluble forms of GFRa4 have a non-conserved D3 domain with a significant homology only up to the first a-helix, where only one of the cysteine bridges seems to be preserved (Figure 1a) .
In order to characterize soluble GFRa4, we established a stable cell line (mouse neuroblastoma Neuro 2a) expressing an N-terminally FLAG-tagged mouse soluble GFRa4, which is secreted into the medium (Figure 1e ). The molecular weight of the expressed protein corresponds to the calculated 21 kDa (including a double FLAG-tag (ASDYKDDDDKAS DYKDDDDKAS) and excluding the endoplasmic reticulum signal sequence, see Figure 1e ). As shown in Figure 1a , the non-homologous part of the D3 domain of mouse soluble GFRa4 harbors two to three new cysteine residues. These new cysteine residues could be involved in the formation of intermolecular cysteine bridges, and could thereby contribute to a spontaneous dimerization of the receptor. Therefore, we analysed the dimerization of the mouse soluble GFRa4 under reducing and non-reducing conditions, and found that a portion of the receptor indeed forms dimers ( Figure 1e ). As GFRa1 D2 has been postulated to interact with RET (Leppa¨nen et al., 2004) (Figure 2a ), using the nonlinear regression analysis program Prism 3.02 (GraphPad Prism Software, San Diego, CA, USA). From these experiments, we conclude that mouse soluble GFRa4 has the capacity to bind PSPN with a binding constant comparable to that of mouse GPI-anchored GFRa4 (2 nM) (Figure 2a ). This result is in line with previously published data which predict that D2 is central to the binding of GDNF to the GFRa1 receptor and of artemin to GFRa3 receptor (Scott and Iba´n˜ez, 2001; Leppa¨nen et al., 2004; Wang et al., 2006) . It is also supported by our recent finding that the purified D2 from GFRa1 has the capacity to bind GDNF (data not shown).
Translation of full-length PSPN has previously been shown to occur only from the spliced variant of its mRNA (Milbrandt et al., 1998) . Therefore, we first verified by RT-PCR that the stable cell line did not express the spliced mRNA encoding full-length PSPN ( Figure 2b ). Furthermore, the absence of PSPN expression in Neuro 2a cells is supported by previously published data showing that exogenously added PSPN induces a robust phosphorylation of RET in GFRa4-GPI transfected Neuro 2a cell lines (Yang et al., 2004) . With the aid of Amicon Ultra-15 (Millipore, 10 kDa cut-off), we concentrated soluble GFRa4 from the serum-free RPMI 1640 medium (80 Â ) of Neuro 2a cells expressing the N-terminally FLAG-tagged mouse soluble GFRa4. This 80 Â concentrate, which is hereafter called sGFRa4-concentrate, was used with or without PSPN to investigate if the mouse soluble GFRa4 has the capacity to interact with, and activate, RET. The sGFRa4-concentrate was added to naive Neuro 2a cells that endogenously express high levels of RET, but no GFRa4 receptors (Yang et al., 2004) . After lysis, RET was immunoprecipitated from the samples and the precipitates were analysed by Western blotting with FLAG antibodies. To ensure equal precipitation of RET in all samples, the precipitates were also analysed with RET antibodies (Figure 2c ). Contradictory results have previously been reported on whether the GFRa1 can associate with RET in the absence of the ligand (Eketja¨ll et al., 1999) , or only in the presence of the ligand (Tansey et al., 2000) . Our co-immunoprecipitation assays show that the soluble GFRa4 receptor interacts with RET already in the absence of its ligand PSPN. In order to assay if the soluble GFRa4 also has the capacity to activate RET, we added the sGFRa4-concentrate to naive Neuro 2a cells and immunoprecipitated RET from the lysates of these samples. The myelin basic protein has previously been reported to function as an exogenous substrate in in vitro kinase assays with kinase activated RET (Asai et al., 1995; Kato et al., 2000) . The result of our in vitro kinase assay (Figure 2d ) is in line with our co-immunoprecipitation results, and shows that soluble GFRa4 activates RET both in the absence and presence of PSPN.
Signalling through RET has been reported to promote neuronal survival through the PI-3 kinase/ AKT signalling pathway (Kodama et al., 2005) , and we therefore set out to determine if the mouse soluble GFRa4 without PSPN could activate the PI-3 kinase/ AKT pathway and promote cell survival. The biochemical detection of activated downstream signalling was Figure 1 Molecular characterization of soluble GFRa4. (a) A sequence alignment of D2 and D3 domains of rat GFRa1, mouse GPIanchored GFRa4 (mGFRa4-GPI), mouse soluble GFRa4 (mGFRa4-sol), the putative human soluble GFRa4 (hGFRa4-sol), as well as the two putative soluble mutant forms of human GFRa4 (hSCa and hSCb) (Vanhorne et al., 2005) . The conserved cysteines are highlighted in yellow, and the putative disulfide bridges are numbered as in the homologous rat GFRa1 D3 (Leppa¨nen et al., 2004) and in human GFRa3 D2 (Wang et al., 2006) shown in (c). The cysteines not following the conserved disulfide pattern are highlighted in magenta. The conserved amino-acid triplet RRR reported to be important for GFRa1/GDNF binding (Scott and Iba´n˜ez, 2001; Leppa¨nen et al., 2004) and GFRa3/artemin binding (Wang et al., 2006) is highlighted in red. The alpha helices are indicated for domain 2 as shown in (c) and for domain 3 as in Leppa¨nen et al. (2004) . The sequence alignment was generated with CLUSTALW (Thompson et al., 1994) . (b) A ribbon diagram model of the mouse GFRa4 D2 with a-helices shown as coils. The Ca-atoms corresponding to the GFRa1 RRR triplet are highlighted in blue. The cysteines involved in the putative disulfide bridges shown as a ball-and-stick representation, and the disulfide bridges are highlighted with yellow lines. N-and C-termini are also shown. (c) The template used for modelling, a ribbon diagram of the crystal structure of GFRa3 D2 (Wang et al., 2006) is shown in (b). The alpha helices are labelled from a1 to a6 from N-to C-terminus. Disulfide bridges are labelled similarly from 1 to 5 and highlighted with yellow lines. The mouse GFRa4 D2 model was prepared using the automated protein homology-modelling server Swiss-Model (Schwede et al., 2003) . The figures were prepared with MOLSCRIPT (Kraulis, 1991) and RASTER3D (Merritt and Bacon, 1997) 4 and 6) . In lanes 1 and 2, the samples were mixed with a reducing Laemmli buffer and boiled for 5 min; in lanes 3 and 4, the samples were mixed with a non-reducing sample buffer and boiled for 2 min; in lanes 5 and 6, the samples were mixed with the same non-reducing sample buffer without boiling. The samples were analysed by 15% SDS-PAGE and subsequent Western blotting with antibodies to the FLAG-epitope.
(For figure see previous page) Figure 3a) . Furthermore, the ability of the FLAGtagged sGFRa4 to activate PI-3 kinase/AKT can be blocked by FLAG antibodies and RET extracellular domain, which shows that signalling is dependent both on sGFRa4 as well as RET (Figure 3b ). The survival assays ( Figure 3c ) were performed in transiently transfected rat 7 days postnatal cerebellar granule neurons (CGNs), which previously have been used to characterize the functionality of different GFRa receptors (Tansey et al., 2000) . CGNs do not endogenously express RET, GFRa4 or PSPN (Yang et al., 2004) . Our data from the survival assay are consistent with the activation of both RET and the PI-3 kinase/AKT pathway and show that mouse soluble GFRa4 can signal through RET even in the absence of PSPN. This was determined with three different types of controls. In the first control, we asked if the sGFRa4-concentrate could promote a survival response in non-transfected CGNs (which do not express RET), and found that the response is fully RET-dependent. In the second control, we attempted to determine whether the activity of the FLAG-tagged soluble GFRa4 could be blocked by anti-FLAG antibodies. Here, we found that both an addition of FLAG-antibodies directly to the medium, as well as a Lindfors et al. (2006) . No spliced PSPN transcript was detected in Neuro 2a cells. cDNA from the adrenal gland was used as a positive control. (c) Co-immunoprecipitation of FLAG-tagged mouse soluble GFRa4 and RET. The sGFRa4-concentrate (GFRa4-sol) was added þ /À PSPN (100 ng/ ml) to non-transfected Neuro2a cells that were lysed. Untreated cells, as well as cells treated with medium from naive Neuro 2a cells (naive N2a), were included as controls. RET was immunoprecipitated with RET-antibodies, and the precipitates were analysed with antibodies to the FLAG-epitope and RET. (d) In vitro kinase assay. The sGFRa4-concentrate (GFRa4-sol) was added in the absence or presence of PSPN (100 ng/ml) to naive, starved Neuro 2a cells, and incubated for 30 or 60 min. Untreated cells and cells treated with medium from naive Neuro 2a cells (naive N2a), or medium from Neuro 2a cells transfected with the GPI-anchored splice variant of mouse (GFRa4-GPI), were included as controls. RET was immunoprecipitated from each lysate and the precipitate was resuspended in the kinase buffer with 2 mg myelin basic protein (MBP) and 2 mCi [g-32 P]ATP. The kinase reaction was carried out at 301C for 20 min, and terminated by adding 2 Â Laemmli sample buffer. The samples were loaded on a 4-20% gradient SDS-PAGE, which was dried and analysed by autoradiography.
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withdrawal of the FLAG-tagged soluble GFRa4 protein from the medium by immunoprecipitation, reduced the survival response dramatically. In the third control, we asked whether concentrated media from either naive Neuro 2a, or Neuro 2a cells which overexpress GPIanchored GFRa4, could promote a survival response. We found that the media in both these cases were inactive.
Recently, we have reported that PSPN mediates differentiation in PC6-3 cells transfected with GPIanchored GFRa4 (Yang et al., 2004) . The PC6-3 cell line is a clone of rat PC12 cells that expresses low levels of endogenous RET. Here, we show that soluble GFRa4 also has the capacity to induce neurite outgrowth in these cells (Figure 4 ). We and others have previously shown that soluble GFRa1 (both full-length and D1-truncated forms) can induce an activation of RET only in the presence of GDNF (Paratcha et al., 2001; Virtanen et al., 2005) . A representative RET-phosphorylation assay with soluble GFRa1 is shown in Supplementary Figure 1 . Our results with soluble GFRa4 show that the soluble receptor can induce neurite outgrowth even in the absence of PSPN.
It is generally assumed that the dimeric GFLs induce the dimerization of the GFRa receptors, which in turn trigger the dimerization and activation of RET. In the case of the mouse soluble GFRa4 receptor, it is tempting to speculate that its ability to activate RET directly could be owing to the non-conserved cysteine residues in D3 domain. These residues may be involved in the formation of intermolecular cysteine bridges, thereby giving rise to dimeric GFRa4 receptor complexes in the absence of PSPN (Figure 1e) . Recently, a mutation that gives rise to two putative forms of soluble GFRa4 receptors was reported to be involved in a more aggressive disease course of MEN 2 (Vanhorne et al., 2005) . As these mutated forms of the GFRa4 receptor also harbor non-conserved cysteine residues in D3 (Figure 1a) , it remains to be determined if the described phenotype could be caused by the formation of covalently linked dimeric GFRa4 receptor complexes. Our findings also offer an insight into MEN 2 cases where RET is not mutated. Figure 2d were included. The selective inhibitor of PI-3 kinase, LY 294002, was also included as a control. In this control, the cells were pre-treated with LY 294002 at 20 mM for 1 h before adding the sGFRa4-concentrate in the presence of the inhibitor (30 min). DMSO is a solvent for the inhibitor, and was therefore used as a control. The extracts were analysed by Western blotting with antibodies to phospho-AKT (pAKT). Equal loading of the samples was ensured by re-probing the membrane with antibodies to AKT. (b) Inhibition of the PI-3 kinase/AKT-activation in Neuro 2a cells. The sGFRa4-concentrate was pre-incubated with either FLAGantibodies (FLAG ab) at 3.5 mg/ml (Sigma AQ), or RET extracellular domain protein (RET ECD; R&D SystemsAQ) at 7 mg/ml before the concentrate was added to the Neuro 2a cells.
The assay was performed as in (a). (c) Cell survival assay in CGNs. On day 5 of culture, the neurons were co-transfected with EGFP and RET as indicated in the figure. After a 24-h transfection, the initial number of EGFP-positive cells was counted in designated fields (around 200 cells). Where indicated, the cultures were subsequently switched from high potassium (25 mM) with serum (K25 þ S) to low potassium (5 mM) medium without serum (K5ÀS). Concentrated media from mock transfected Neuro 2a cells (mock N2a), naive Neuro 2a cells (naive N2a), the GFRa4-GPI stable cell line (GFRa4-GPI) and the GFRa4-soluble stable cell line (GFRa4-sol) were exchanged for K5ÀS with the aid of Amicon Ultra-15 columns and added to the CGNs. PSPN (100 ng/ ml) or antibodies to the FLAG-epitope (FLAG ab) were added (1 mg/ml) as indicated. As an additional control, the FLAG-tagged GFRa4-sol was immunoprecipitated (IP) from the media before adding it to the CGNs. The side effects of FLAG antibodies were excluded by adding the antibodies to CGNs grown in K25 þ S medium. EGFP-positive CGNs were re-counted after 3.5 days. For each treatment, two parallel samples were counted and the assay was repeated three times.
